By Daniella Parra
Imviva Biotech said data showed its CTA313 drug resulted in 50% of patients going into remission for systemic lupus.
Many patients experience incomplete responses, recurrent flares and long-term treatment-related toxicity, it said.
“The clinical activity observed with CTA313 in systemic lupus erythematosus is highly encouraging, with 100% of patients achieving an SRI-4 response and 50% reaching remission at a median follow up of six months,” said Ben Capoccia, Director of Translation Medicine and Clinical Research at Imviva Biotech.
READ MORE
Final Agenda and Registration – 2nd Princeton CorpGov Forum: Endowments, Activism and Entertainment
Never Miss our Weekly Highlights HERE
